Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1
Yoshinori Ozono, Satoru Hasuike, Hisayoshi Iwakiri, Kenichi Nakamura, Yuri Yamada, Yuka Takaishi, Mitsue Sueta, Tadashi Miike, Yoshihiro Tahara, Shojiro Yamamoto, Kotaro Shide, Tomonori Hidaka, Yoko Kubuki, Kazuya Shimoda, Department of Gastoroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1601, Japan
Kenji Nagata, Mai Tsuchimochi, Kazuya Shimoda, Department of Liver Disease, University of Miyazaki Hospital, Miyazaki 889-1601, Japan
Kazunori Kusumoto, Toshimasa Ochiai, Department of Internal Medicine, Koga General Hospital, Miyazaki 880-0041, Japan
Junya Kato, Naoto Komada, Department of Internal Medicine, National Hospital Organization Miyakonojo Medical Center, Miyazaki 885-0014, Japan
Shuichi Hirono, Department of Internal Medicine, Hirono Naika Clinic, Miyazaki 880-0925, Japan
Kazuo Kuroki, Department of Internal Medicine, Kushima Municipal Hospital, Miyazaki 888-0001, Japan
Masafumi Shigehira, Department of Internal Medicine, Shigehira Clinic, Miyazaki 885-0005, Japan
Author contributions: Ozono Y and Nagata K contributed to the study conception and design; Hasuike S, Iwakiri H, Nakamura K, Tsuchimochi M, Yamada Y, Takaishi Y, Sueta M, Miike T, Tahara Y, Yamamoto S, Kusumoto K, Ochiai T, Kato J, Komada N, Hirono S, Kuroki K and Shigehira M contributed to data acquisition; Shide K, Hidaka T, Kubuki Y and Shimoda K contributed to drafting the manuscript and revisions; all authors gave final approval of the version to be published.
Institutional review board statement: This study was approved by the Research Ethics Committee of the University of Miyazaki.
Informed consent statement: Informed consent was obtained from all the patients.
Conflict-of-interest statement: There are no conflict-of-interests involved in the article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Kenji Nagata, MD, PhD, Department of Liver Disease, University of Miyazaki Hospital, 5200 Kihara, Kiyotake, Miyazaki 889-1601, Japan. firstname.lastname@example.org
Telephone: +81-985-859121 Fax: +81-985-855194
Received: August 25, 2017
Peer-review started: August 26, 2017
First decision: September 20, 2017
Revised: October 10, 2017
Accepted: November 3, 2017
Article in press: November 3, 2017
Published online: December 28, 2017